IP Verse

Novartis Pharma Ag opposition analysis

COMPANY ANALYSIS

Latest patents of Novartis Pharma Ag opposed by its competitors

Patent:
EP2784084
Grant Date:
Oct 4, 2023
Title:
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof
Oppositions:
5
Patent:
EP3345602
Grant Date:
Apr 6, 2022
Title:
Rapamycin Derivative For Treating Advanced Solid Tumours
Oppositions:
3
Patent:
EP3003316
Grant Date:
Jul 22, 2020
Title:
Combination Therapies For Cancer
Oppositions:
1
Patent:
EP2340828
Grant Date:
Jul 15, 2020
Title:
Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
Oppositions:
8
Patent:
EP3351246
Grant Date:
Sep 18, 2019
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Oppositions:
9
Patent:
EP3342411
Grant Date:
Aug 21, 2019
Title:
Rapamycin Derivative For Treating Pancreas Cancer
Oppositions:
10
Patent:
EP3143995
Grant Date:
Dec 5, 2018
Title:
A Rapamycin Derivative For Treating Lung Cancer
Oppositions:
7
Patent:
EP1983984
Grant Date:
Mar 7, 2018
Title:
Tuberous Sclerosis Treatment
Oppositions:
4

Competitors of Novartis Pharma Ag

STADA ARZNEIMITTEL AG

ETHYPHARM

ACCORD HEALTHCARE LTD

Want to track Novartis Pharma Ag?

Feel free to send us a message here and we will get back to you